Texas power demand breaks May record again as prices soar in heat wave
By Scott DiSavino (Reuters) -Power demand in Texas broke the record for the month of May for a second time this week on Friday as
Putin wants Ukraine ceasefire on current frontlines, sources say
By Guy Faulconbridge and Andrew Osborn MOSCOW/LONDON (Reuters) – Russian President Vladimir Putin is ready to halt the war in Ukraine with a negotiated ceasefire
SpaceX mulling tender offer at $200 billion valuation, Bloomberg News reports
(Reuters) -Elon Musk’s SpaceX has initiated discussions about selling existing shares in a deal that could value the company at roughly $200 billion, Bloomberg News
Global minimum tax deal on multinationals set to fail, G7 chair says
By Giuseppe Fonte STRESA, Italy (Reuters) – An accord over a global minimum tax on multinationals will not be finalised by June as previously planned,
Exclusive-Nvidia cuts China prices in Huawei chip fight, sources say
By Fanny Potkin SINGAPORE (Reuters) – Nvidia’s most advanced AI chip it developed for the China market has got off to a weak start, with
Boeing faces ‘long road’ on safety issues, US FAA says
WASHINGTON (Reuters) – U.S. planemaker Boeing faces a “long road” to address safety issues, the head of the Federal Aviation Administration said on Thursday as
Medtronic beats quarterly profit estimates on medical devices strength
(Reuters) -Health tech firm Medtronic beat Wall Street estimates for quarterly profit and revenue on Thursday, as a post-pandemic pickup in surgical volumes at hospitals
Medtronic beats fourth-quarter estimates on strength in medical devices
(Reuters) -Health tech firm Medtronic beat Wall Street estimates for quarterly profit and revenue on Thursday, as a pickup in surgical volumes at hospitals lifted
Nasdaq jumps as Nvidia results drive up chip stocks
By Ankika Biswas and Lisa Pauline Mattackal (Reuters) – The tech-heavy Nasdaq and the benchmark S&P 500 opened at record highs on Thursday as chip
Biogen to buy Human Immunology Biosciences for up to $1.8 billion deal
(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, gaining access to targeted therapies